Citigroup released a research report stating that SINO BIOPHARM (01177) announced the acquisition of Hygieia, a private biotech company specializing in small interfering RNA (siRNA) drugs, for a maximum base consideration of 1.2 billion yuan. The bank believes this acquisition further enhances SINO BIOPHARM's innovation capabilities and out-licensing potential, solidifying its position as a leading innovative pharmaceutical company in China. It maintains a target price of HK$10.8 and a "Buy" rating. Hygieia has developed multiple differentiated delivery platforms, and its R&D pipeline includes drug candidates such as Kylo-11, Kylo-12, Kylo-0603, HJY-10, and HJY-02. Through this acquisition, SINO BIOPHARM will establish a next-generation cardiovascular innovation pipeline, strengthen its presence in the weight management and metabolic diseases sector, and expand into new frontiers of the chronic disease management market.